Zhang Shu, Ye Yun, Zhang Qiang, Luo Yang, Wang Zi-Chen, Wu Yi-Zhe, Zhang Xiang-Pu, Yi Chuan
Hubei Key Laboratory of Pollution Damage Assessment & Environmental Health Risk Prevention & Control, Hubei Provincial Academy of Eco-Environmental Sciences, Wuhan, Hubei, 430000, PR China.
Technical Review Center for Administrative Licensing, Hubei Provincial Administration for Market Regulation, Wuhan, Hubei, 430000, PR China.
Future Med Chem. 2023 Aug;15(16):1527-1548. doi: 10.4155/fmc-2023-0138. Epub 2023 Aug 23.
Chemotherapy is a critical treatment modality for cancer patients, but multidrug resistance remains one of the major challenges in cancer therapy, creating an urgent need for the development of novel potent chemical entities. Azoles, particularly pyrazole, could interact with different biological targets and exhibit diverse biological properties including anticancer activity. Many clinically used anticancer agents own an azole moiety, demonstrating that azoles are privileged and pivotal templates in the discovery of novel anticancer chemotherapeutics. The present article is an attempt to highlight the recent advances in pyrazole-azole hybrids with anticancer potential and discuss the structure-activity relationships, covering articles published from 2018 to present, to facilitate the rational design of more effective anticancer candidates.
化疗是癌症患者的关键治疗方式，但多药耐药性仍然是癌症治疗中的主要挑战之一，这迫切需要开发新型强效化学实体。唑类，特别是吡唑，可与不同的生物靶点相互作用，并表现出包括抗癌活性在内的多种生物学特性。许多临床使用的抗癌药物都含有唑类部分，这表明唑类是发现新型抗癌化疗药物的优势和关键模板。本文旨在突出具有抗癌潜力的吡唑-唑类杂合物的最新进展，并讨论构效关系，涵盖2018年至今发表的文章，以促进更有效抗癌候选药物的合理设计。
